Data Product Manager Lead, 23andMe
$195.6-293.4k
2+ days a week in office (Sunnyvale, CA)
Genetic testing and DNA analysis
Open for applications
Genetic testing and DNA analysis
501-1000 employees
Open for applications
$195.6-293.4k
2+ days a week in office (Sunnyvale, CA)
501-1000 employees
Company mission
To help people access, understand, and benefit from the human genome.
Role
Who you are
- 8+ years experience in product management
- Proven ability to lead a team to meet concrete milestones
- Strong analytical skills
- Ability to build relationships and effectively collaborate with all levels of the organization, from C-level to individual contributors
- Ability to manage and influence through persuasion, negotiation, and consensus building
- Enthusiasm and creativity to inspire others
- Deep experience with building enterprise B2B products for healthcare and life science customers
- History of developing and successfully launching data products in the past
Desirable
- Advanced degree (MS, PhD) in a relevant life sciences field
- Scientific research experience; solid understanding of genetics-driven research and drug target discovery (e.g., genome-wide association studies (GWAS))
- Familiarity with UX and information architecture best practices
- Experience building up and leading a PM team
What the job involves
- As the Data Product Manager Lead you will work on transforming the world’s largest research-consented recontactable genetics database into a powerful product that can help accelerate the discovery, validation, and distribution of cures for some of the most destructive health conditions that plague us today
- Build enterprise products that are driven by 23andMe’s proprietary genetic data and analytical capabilities that address meaningful needs for 23andMe’s external partners (e.g., pharmaceutical companies, research institutions)
- Collaborate with research leaders to establish a vision and strategy for product development that builds on ongoing projects
- Establish cross-functional relationships with research (computational scientists and bioinformaticians), therapeutics, business development, engineering, marketing, and design to define product requirements, specify scope, and drive timelines
- Create detailed road maps, prioritize relentlessly, and communicate trade-offs internally
- Define success metrics, measure, and evaluate the impact of product efforts
- Analyze and understand data, and leverage that understanding to make data-driven decisions
- Work closely with 23andMe scientists and the business development team to communicate the value of the product to potential customers and gather feedback about what would help advance success rates in drug discovery and other applications of the data
Share this job
View 1 more job at 23andMe
Insights
10% employee growth in 12 months
Company
Company benefits
- Comprehensive health, vision, and dental plans
- Family planning, support, and leave for parents
- Mental healthcare
- Student loan assistance
- Volunteer time off
- Dog friendly office
Funding (last 2 of 10 rounds)
Dec 2020
$82.5m
SERIES F
Jul 2018
$300m
GROWTH EQUITY VC
Total funding: $802.9m
Our take
23andMe offers its customers a vision into their ancestry and health through genetic testing carried out via kits sent through the mail. Results can show users their risk of more than 50 health conditions thanks to a tube of saliva at one end and a lot of technology at the other.
This access to genetic insight has helped the company sell more than 15 million test kits in the last 15 years. This remains the core component of the business. Access to millions of customers DNA however has given the company a vast collection of genetic material, allowing 23andMe to expanded into the drug development space where it is collaborating with pharmaceutical giant GlaxoSmithKline.
23andMe is not without competition, with other big names including Ancestry and MyHeritage. However, with a valuation of $3.5 billion, it remains one of the largest, with pockets deep enough to pursue many of its growth programs. In mid-2021, the company went public through a SPAC merger with a company founded by Richard Branson. 23andMe intends to use the merger to invest in its health and therapeutics division.
Kirsty
Company Specialist at Welcome to the Jungle